Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 34Paraganglioma 6Meningioma 6Gastro-enteropancreatic neuroendocrine tumor 6Pheochromocytoma 5Carcinoma, Neuroendocrine 4Neuroblastoma 3Carcinoid Tumor 3Adenoma, Islet Cell 3Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Merkel Cell 2Carcinoma, Medullary 2Somatostatinoma 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Extensive Stage Small Cell Lung Cancer 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × lutetium Lu 177 dotatate × Clear all
NCT07012330 2025-06-10

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Erasmus Medical Center

Phase 2 Terminated
111 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡